Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | FURIN | P09958 | 10/20 | 0.38 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.36 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.36 |
| ▸ | Q9HBH1 | 1/20 | 0.36 | |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23498013 | 0.99 | HTR2A (0.39) | HTR2AFURINMAP1LC3BSSTR3PDF | |
| SCHEMBL17490581 | 0.99 | HTR2A (0.39) | HTR2AFURINMAP1LC3BSSTR3PDF | |
| SCHEMBL23498015 | 0.99 | HTR2A (0.39) | HTR2AFURINMAP1LC3BSSTR3PDF | |
| SCHEMBL19731615 | 0.94 | FURIN (0.39) | HTR2AFURINMAP1LC3BSSTR3PDF | |
| SCHEMBL22691442 | 0.94 | FURIN (0.39) | HTR2AFURINMAP1LC3BSSTR3PDF | |
| SCHEMBL29649550 | 0.94 | PDF (0.38) | FURINSSTR3PDFFOLH1 | |
| SCHEMBL15223879 | 0.93 | HTR2A (0.39) | HTR2AFURINMAP1LC3BSSTR3PDF | |
| SCHEMBL18792771 | 0.93 | HTR2A (0.39) | HTR2AFURINMAP1LC3BSSTR3PDF | |
| SCHEMBL17312903 | 0.93 | HTR2A (0.40) | HTR2AFURINMAP1LC3BSSTR3PDF | |
| SCHEMBL26015668 | 0.93 | HTR2A (0.40) | HTR2AFURINMAP1LC3BSSTR3PDF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209119-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | DYNE THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240016952-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY | DYNE THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230346966-A1 | MUSCLE-TARGETING COMPLEXES AND USES THEREOF IN TREATING MUSCLE ATROPHY | DYNE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230330562-A1 | METHODS OF PREPARING PROTEIN-OLIGONUCLEOTIDE COMPLEXES | DYNE THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230285582-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | DYNE THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230256112-A1 | ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY AND USES THEREOF | Dyne Therapeutics, lnc. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230226212-A1 | MUSCLE-TARGETING COMPLEXES AND USES THEREOF | DYNE THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-11648318-B2 | Anti-transferrin receptor (TFR) antibody and uses thereof | DYNE THERAPEUTICS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016952-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY | MUSK, MYOF, MYLK2 | HTR2A 2926/4885FURIN 3296/4885MAP1LC3B 1947/4885 |
| US-20230285582-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | MUSK, MYOF, UTRN | HTR2A 3954/4885FURIN 3231/4885MAP1LC3B 2759/4885 |
| US-20230346966-A1 | MUSCLE-TARGETING COMPLEXES AND USES THEREOF IN TREATING MUSCLE ATROPHY | MYOF, MUSK, MYO3A | HTR2A 3548/4885FURIN 1917/4885MAP1LC3B 1753/4885 |
| US-20230256112-A1 | ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY AND USES THEREOF | TFRC, FTH1, FOLR1 | HTR2A 2341/4885FURIN 3858/4885MAP1LC3B 2019/4885 |
| US-11648318-B2 | Anti-transferrin receptor (TFR) antibody and uses thereof | TFRC, FTH1, FOLR1 | HTR2A 2341/4885FURIN 3858/4885MAP1LC3B 2019/4885 |
| US-20230226212-A1 | MUSCLE-TARGETING COMPLEXES AND USES THEREOF | MUSK, MYOF, MYLK2 | HTR2A 2160/4885FURIN 3026/4885MAP1LC3B 2168/4885 |
| US-20240209119-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | UTRN, MUSK, SMN1; SMN2 | HTR2A 3306/4885FURIN 1685/4885MAP1LC3B 3574/4885 |
| US-20230330562-A1 | METHODS OF PREPARING PROTEIN-OLIGONUCLEOTIDE COMPLEXES | PHAX, RAB5IF, CD2BP2 | HTR2A 4234/4885FURIN 2219/4885MAP1LC3B 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.